Europe Hla Typing Transplant Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2021 –2028 |
 Taille du marché (année de référence) |
USD 194.35 Million |
 Taille du marché (année de prévision) |
USD 344.87 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation, par produits et services (réactifs et consommables, instruments, logiciels et services), technologie (dosages moléculaires basés sur le séquençage, technologies de dosage moléculaire, technologies de dosage non moléculaire), type de transplantation (transplantation d'organe solide, transplantation de cellules souches hématopoïétiques), application (applications diagnostiques, applications de recherche), utilisateur final (laboratoires de référence indépendants, hôpitaux et centres de transplantation, laboratoires de recherche et instituts universitaires), pays (Royaume-Uni, France, Italie, Espagne, Suisse, Russie, Pays-Bas, Turquie, Belgique et reste de l'Europe) Tendances et prévisions de l'industrie jusqu'en 2028.
Analyse et perspectives du marché : Typage des antigènes leucocytaires humains (HLA) pour le marché européen des transplantations
Le marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation devrait connaître une croissance significative au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation croît avec un TCAC de 7,8 % au cours de la période de prévision de 2021 à 2028 et devrait atteindre 344,87 millions USD d'ici 2028 contre 194,35 millions USD en 2020. La demande croissante de procédures de transplantation d'organes agit comme un moteur de la croissance du marché mondial du typage des leucocytes humains pour la transplantation.
Le typage des antigènes leucocytaires humains (HLA) est utilisé pour établir une correspondance entre les patients et les donneurs pour les greffes de moelle osseuse ou de sang de cordon. Les HLA sont des protéines – ou marqueurs – présentes sur la plupart des cellules du corps. Le système immunitaire utilise ces marqueurs pour reconnaître les cellules qui appartiennent au corps et celles qui n'en font pas partie.
Les recherches ont montré qu'un donneur doit correspondre à au moins 6 marqueurs HLA. Plusieurs fois, une correspondance plus étroite est nécessaire. La meilleure correspondance est trouvée grâce à des tests détaillés. Comme certains types HLA sont plus courants que d'autres, certains patients peuvent avoir plus de mal à trouver un donneur compatible. Certains types HLA sont plus fréquents dans certains groupes raciaux et ethniques.
Une correspondance étroite entre les marqueurs HLA du donneur et ceux du patient est essentielle pour une transplantation réussie. La correspondance HLA favorise la croissance et le développement de nouvelles cellules sanguines saines (appelées greffe) et réduit le risque d'une complication post-transplantation appelée réaction du greffon contre l'hôte (GVHD) .
La forte demande de don d'organes, l'augmentation des innovations et des technologies et le lancement de nouveaux produits propulsent également la croissance du marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation.
Un nombre croissant de personnes sont touchées par les troubles HLA qui nécessitent un traitement très efficace et avancé pour minimiser les risques pendant le traitement. Les systèmes de santé ont besoin de médicaments très avancés pour de nombreux types différents de troubles HLA pendant le traitement des patients. Par conséquent, les principaux acteurs du marché se concentrent fortement sur le lancement et l'approbation des produits. En outre, le gouvernement et les organismes de réglementation soutiennent les acteurs du marché en vertu de l'approbation des produits.
L'augmentation des lancements de produits constitue une opportunité pour ce marché et devrait stimuler la croissance du marché pour stimuler la demande de typage des leucocytes humains à l'échelle mondiale pour le marché de la transplantation.
Les recherches sur l'antigène leucocytaire humain (HLA) sont une molécule largement étudiée impliquée dans l'immunité et les technologies NGS ont révolutionné la procédure de typage HLA en fournissant une technologie rapide et rentable. On s'attend à ce que le manque de professionnels qualifiés soit le principal défi pour la croissance future du typage de l'antigène leucocytaire humain (HLA) pour le marché mondial des transplantations.
Le rapport sur le marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché, les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Marché et taille du marché du typage des antigènes leucocytaires humains (HLA) pour la transplantation en Europe
Le marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation est segmenté en fonction des produits et services, de la technologie, du type de transplantation, de l'application et de l'utilisateur final. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base des sous-produits et services, le marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation est segmenté en réactifs et consommables, instruments, logiciels et services. En 2021, le segment des instruments devrait dominer le marché en raison de la forte demande de transplantation d'organes qui a rapidement augmenté.
- Sur la base de la technologie, le marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation est composé de technologies d'analyse moléculaire et de technologies d'analyse non moléculaire. En 2021, le segment des technologies d'analyse moléculaire devrait dominer le marché en raison de la sensibilisation croissante à la maladie.
- On the basis of transplant type, Europe human leukocyte antigen (HLA) typing for transplant market is segmented solid organ transplant and haematopoietic stem cell transplant. In 2021, solid organ transplant segment is expected to dominate the market because of increasing prevalence of this disease type among target population.
- On the basis of application, the Europe human leukocyte antigen (HLA) typing for transplant market is segmented into diagnostic applications and research application. In 2021, diagnostic applications segment is expected to dominate the market because of high pool of patients with cancer and genetic diseases.
- On the basis of end user, the Europe human leukocyte antigen (HLA) typing for transplant market is segmented into independent reference laboratories, hospitals and transplant centres, research laboratories and academic institutes. In 2021, hospitals & transplant centers segment is expected to dominate the market owing to the rising product launches by the key market players.
Europe Human Leukocyte Antigen (HLA) Typing for Transplant Market Country Level Analysis
The Europe human leukocyte antigen (HLA) typing for transplant market is analyzed and market size information is provided based on country, products and services, technology, transplant type, application, and end user.
Countries covered in the Europe human leukocyte antigen (HLA) typing for transplant market report are Germany, France, U.K., Hungary, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and rest of Europe.
U.K. is expected to dominate the Europe human leukocyte antigen (HLA) typing for transplant market due to increasing rising government funding in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising Healthcare Expenditure and Escalation in Innovations and Technologies in the Europe Human Leukocyte Antigen (HLA) Typing for Transplant Market are Creating New Opportunities for Players in the Europe Human Leukocyte Antigen (HLA) Typing for Transplant Market
Le marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation vous fournit également une analyse de marché détaillée pour la croissance de chaque pays dans une industrie particulière avec les ventes du marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation, l'impact des progrès sur le marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation et les changements dans les scénarios réglementaires avec leur soutien au marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation au cours de la période 2011-2019.
Paysage concurrentiel et analyse des parts de marché du typage des antigènes leucocytaires humains (HLA) pour la transplantation en Europe
Le paysage concurrentiel du marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'ampleur du produit, la domination des applications et la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées au marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation.
Les principaux acteurs couverts dans le rapport sont Thermo Fisher Scientific Inc., Illumina, Inc., Luminex Corporation, QIAGEN, CareDX, Inc., Immucor Inc., Bio Rad Labaratories, Inc., Takara Bio Inc., BD, Fujirebio, TBG Diagnostics Limited et GenDx.
Les analystes DBMR comprennent les atouts concurrentiels et fournissent une analyse concurrentielle pour chaque concurrent séparément.
De nombreux lancements de produits et accords sont également initiés par les entreprises du monde entier, ce qui accélère encore davantage le marché européen du typage des antigènes leucocytaires humains (HLA) pour la transplantation.
Par exemple,
- En octobre 2017, les kits SBT HLAssure SE de TBG ont reçu l'approbation de la CFDA chinoise pour une utilisation clinique. Il s'agit de la première approbation d'un kit de typage HLA haute résolution en Chine. Cela a permis à l'entreprise de renforcer sa présence en Chine et de stimuler la croissance du marché
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT & SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 AVERAGE PRICE/TEST FOR HLA TYPING BY NEXT GENERATION SEQUENCING (USD)
4.2 PESTEL'S MODEL
4.3 PORTER'S 5 FORCES
5 REGIONAL SUMMARY
5.1 EUROPE
5.1.1 OVERVIEW
6 REGULATORY GUIDELINES FOR EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) FOR TRANSPLANT MARKET
6.1 U.S.
6.2 EUROPE
6.3 JAPAN
6.4 INDIA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING DEMAND FOR ORGAN TRANSPLANT PROCEDURES
7.1.2 GROWING TECHNOLOGICAL ADVANCEMENT & INNOVATIONS IN HLA TYPING
7.1.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES IN HLA TYPING
7.1.4 INCREASING CERTAIN DISEASES SUCH AS BLOOD CANCERS, AND GENETIC BLOOD DISORDERS
7.2 RESTRAINTS
7.2.1 HIGH COST OF HLA TYPING FOR TRANSPLANTATION PROCEDURE
7.2.2 LIMITED REIMBURSEMENTS POLICIES FOR ORGAN TRANSPLANT
7.3 OPPORTUNITIES
7.3.1 PRODUCT LAUNCHES, AND AGREEMENT BY MAJOR PLAYERS
7.3.2 RISING GOVERNMENT FUNDING FOR ORGAN DONATIONS
7.3.3 RISING PUBLIC AWARENESS FOR ORGAN TRANSPLANTATION
7.4 CHALLENGES
7.4.1 LESS NUMBER OF DONORS FOR ORGAN DONATION
7.4.2 DEARTH OF SKILLED PROFESSIONALS
8 COVID-19 IMPACT ON HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES
9.1 OVERVIEW
9.2 INSTRUMENTS
9.3 REAGENTS AND CONSUMABLES
9.4 SOFTWARE & SERVICES
10 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY
10.1 OVERVIEW
10.2 MOLECULAR ASSAY TECHNOLOGIES
10.2.1 SEQUENCING-BASED MOLECULAR ASSAYS
10.2.1.1 NEXT-GENERATION SEQUENCING
10.2.1.2 SANGER SEQUENCING
10.2.1.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS
10.2.2 PCR-BASED MOLECULAR ASSAYS
10.2.2.1 SEQUENCE-SPECIFIC PRIMER-PCR
10.2.2.2 REAL-TIME PCR
10.2.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
10.2.2.4 OTHER PCR-BASED MOLECULAR ASSAYS
10.3 NON-MOLECULAR ASSAY TECHNOLOGIES
11 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE
11.1 OVERVIEW
11.2 SOLID ORGAN TRANSPLANT
11.2.1 KIDNEY
11.2.2 LIVER
11.2.3 HEART
11.2.4 LUNG
11.2.5 PANCREAS
11.2.6 OTHERS
11.3 HEMATOPOIETIC STEM CELL TRANSPLANT
11.3.1 STEM CELL TRANSPLANT
11.3.2 BONE MARROW TRANSPLANT
12 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 DIAGNOSTIC APPLICATIONS
12.2.1 ANTIBODY SCREENING
12.2.2 CHIMERISM MONITORING
12.2.3 OTHERS
12.3 RESEARCH APPLICATIONS
13 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS & TRANSPLANT CENTERS
13.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
13.4 INDEPENDENT REFERENCE LABORATORIES
14 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 U.K.
14.1.3 FRANCE
14.1.4 ITALY
14.1.5 SPAIN
14.1.6 SWITZERLAND
14.1.7 RUSSIA
14.1.8 NETHERLANDS
14.1.9 TURKEY
14.1.10 BELGIUM
14.1.11 REST OF EUROPE
15 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 MARKET SHARE ANALYSIS: BY TECHNOLOGY
16.1 SEQUENCING BASED MOLECULAR ASSAYS
16.1.1 NORTH AMERICA
16.1.2 EUROPE
16.1.3 ASIA-PACIFIC
16.1.4 SOUTH AMERICA
16.1.5 MIDDLE EAST AND AFRICA
16.2 NGS SEQUENCING
16.2.1 NORTH AMERICA
16.2.2 EUROPE
16.2.3 ASIA-PACIFIC
16.2.4 SOUTH AMERICA
16.2.5 MIDDLE EAST AND AFRICA
16.3 SANGER SEQUENCING
16.3.1 NORTH AMERICA
16.3.2 EUROPE
16.3.3 ASIA-PACIFIC
16.3.4 SOUTH AMERICA
16.3.5 MIDDLE EAST AND AFRICA
16.4 PCR BASED MOLECULAR ASSAYS
16.4.1 NORTH AMERICA
16.4.2 EUROPE
16.4.3 ASIA-PACIFIC
16.4.4 SOUTH AMERICA
16.4.5 MIDDLE EAST AND AFRICA
16.5 REAL TIME PCR
16.5.1 NORTH AMERICA
16.5.2 EUROPE
16.5.3 ASIA-PACIFIC
16.5.4 SOUTH AMERICA
16.5.5 MIDDLE EAST AND AFRICA
16.6 SEQUENCE-SPECIFIC PRIMER-PCR
16.6.1 NORTH AMERICA
16.6.2 EUROPE
16.6.3 ASIA-PACIFIC
16.6.4 SOUTH AMERICA
16.6.5 MIDDLE EAST AND AFRICA
16.7 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
16.7.1 NORTH AMERICA
16.7.2 EUROPE
16.7.3 ASIA-PACIFIC
16.7.4 SOUTH AMERICA
16.7.5 MIDDLE EAST AND AFRICA
17 COMPANY PROFILE
17.1 THERMO FISHER SCIENTIFIC INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.1.6 SWOT ANALYSIS
17.2 ILLUMINA, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.2.6 SWOT ANALYSIS
17.3 BIO-RAD LABORATORIES, INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.3.6 SWOT ANALYSIS
17.4 QIAGEN
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.4.5.1 ACQUISITION
17.4.6 SWOT ANALYSIS
17.5 ROCHE SEQUENCING (A SUBSIDIARY OF F.HOFFMAN LA-ROCHE LTD.)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.5.6 SWOT ANALYSIS
17.6 BD
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 BIOFORTUNA LIMITED
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 CARE DX, INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 CREATIVE BIOLABS
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.9.3.1 PRODUCT LAUNCH/UPDATE/APPROVAL
17.1 FUJIREBIO
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.10.4.1 CE CERTIFICATION
17.11 GENDX
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 IMMUCOR, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.12.3.1 PROUCT LAUNCH
17.13 LUMINEX CORPORATION
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 OMIXON INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.14.3.1 PRODUCT LAUNCH
17.15 TAKARA BIO INC
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.15.4.1 LICENSING
17.15.5 PRODUCT LAUNCH
17.16 TBG DIAGNOSTICS LIMITED
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AVERAGE PRICE/TEST FOR HLA TYPING BY NEXT GENERATION SEQUENCING
TABLE 2 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BYPRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 EUROPE REAGENTS AND CONSUMABLES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE SOFTWARE & SERVICES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 7 EUROPE MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 EUROPE MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY , 2019-2028 (USD MILLION)
TABLE 9 EUROPE SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY , 2019-2028 (USD MILLION)
TABLE 10 EUROPE PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 11 EUROPE NON-MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 13 EUROPE SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 EUROPE SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE , 2019-2028 (USD MILLION)
TABLE 15 EUROPE HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 EUROPE HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 17 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, REGION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE RESEARCH APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 22 EUROPE HOSPITALS & TRANSPLANT CENTERS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE RESEARCH LABORATORIES & ACADEMIC INSTITUTES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE OTHERS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 26 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 27 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 EUROPE MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 29 EUROPE SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 EUROPE PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 31 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 32 EUROPE SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 33 EUROPE HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 34 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 37 GERMANY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 38 GERMANY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 39 GERMANY MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 40 GERMANY SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 41 GERMANY PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 42 GERMANY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 43 GERMANY SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 44 GERMANY HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 45 GERMANY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 46 GERMANY DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 47 GERMANY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 48 U.K. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 49 U.K. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 50 U.K. MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 51 U.K. SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 52 U.K. PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 53 U.K. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 54 U.K. SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 55 U.K. HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 56 U.K. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 57 U.K. DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 58 U.K. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 59 FRANCE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 60 FRANCE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 61 FRANCE MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 62 FRANCE SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 63 FRANCE PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 64 FRANCE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 65 FRANCE SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 66 FRANCE HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 67 FRANCE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 68 FRANCE DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 69 FRANCE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 70 ITALY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 71 ITALY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 72 ITALY MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 ITALY SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 ITALY PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 ITALY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 76 ITALY SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 77 ITALY HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 78 ITALY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 79 ITALY DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 80 ITALY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 81 SPAIN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 82 SPAIN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 83 SPAIN MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 84 SPAIN SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 85 SPAIN PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 86 SPAIN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 87 SPAIN SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 88 SPAIN HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 89 SPAIN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 SPAIN DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 SPAIN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 92 SWITZERLAND HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 93 SWITZERLAND HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 94 SWITZERLAND MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 95 SWITZERLAND SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 96 SWITZERLAND PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 97 SWITZERLAND HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 98 SWITZERLAND SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 99 SWITZERLAND HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 100 SWITZERLAND HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 101 SWITZERLAND DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 102 SWITZERLAND HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 103 RUSSIA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 104 RUSSIA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 105 RUSSIA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 106 RUSSIA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 107 RUSSIA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 108 RUSSIA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 109 RUSSIA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 110 RUSSIA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 111 RUSSIA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 RUSSIA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 RUSSIA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 114 NETHERLANDS HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 115 NETHERLANDS HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 116 NETHERLANDS MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 117 NETHERLANDS SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 118 NETHERLANDS PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 119 NETHERLANDS HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 120 NETHERLANDS SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 121 NETHERLANDS HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 122 NETHERLANDS HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 123 NETHERLANDS DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 124 NETHERLANDS HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 125 TURKEY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 126 TURKEY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 127 TURKEY MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 128 TURKEY SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 129 TURKEY PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 130 TURKEY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 131 TURKEY SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 132 TURKEY HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 133 TURKEY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 134 TURKEY DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 135 TURKEY HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 136 BELGIUM HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 137 BELGIUM HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 138 BELGIUM MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 139 BELGIUM SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 140 BELGIUM PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 141 BELGIUM HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 142 BELGIUM SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 143 BELGIUM HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 144 BELGIUM HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 145 BELGIUM DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 146 BELGIUM HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 147 REST OF EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION
FIGURE 2 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET:
FIGURE 3 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION
FIGURE 11 INCREASING DEMAND FOR ORGAN TRANSPLANTATION, AND RISING R&D ACTIVITIES IN HLA TYPING ARE EXPECTED TO DRIVE THE EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
FIGURE 16 IN 2021, ESTIMATED NEW CASES OF LEUKEMIA, MYELOMA, AND LYMPHOMA IN THE U.S.
FIGURE 17 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2020
FIGURE 18 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2021-2028 (USD MILLION)
FIGURE 19 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, CAGR (2021-2028)
FIGURE 20 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE
FIGURE 21 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2020
FIGURE 22 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)
FIGURE 23 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, CAGR (2021-2028)
FIGURE 24 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 25 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2020
FIGURE 26 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2021-2028 (USD MILLION)
FIGURE 27 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, CAGR (2021-2028)
FIGURE 28 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, LIFELINE CURVE
FIGURE 29 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2020
FIGURE 30 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 31 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 32 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, 2021-2028 (USD MILLION)
FIGURE 34 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 35 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: END USERS, CAGR (2021-2028)
FIGURE 36 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, LIFELINE CURVE
FIGURE 37 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SNAPSHOT (2020)
FIGURE 38 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020)
FIGURE 39 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 41 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCT & SERVICES (2021-2028)
FIGURE 42 EUROPE HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY SHARE 2020 (%)
FIGURE 43 NORTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 44 EUROPE SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 45 ASIA-PACIFIC SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 46 SOUTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 47 MIDDLE EAST AND AFRICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 48 NORTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 49 EUROPE NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 50 ASIA-PACIFIC NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 51 SOUTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 52 MIDDLE EAST AND AFRICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 53 NORTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 54 EUROPE SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 55 ASIA-PACIFIC SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 56 SOUTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 57 MIDDLE EAST AND AFRICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 58 NORTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 59 EUROPE PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 60 ASIA-PACIFIC PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 61 SOUTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 62 MIDDLE EAST AND AFRICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 63 NORTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 64 EUROPE REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 65 ASIA-PACIFIC REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 66 SOUTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 67 MIDDLE EAST AND AFRICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 68 NORTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 69 EUROPE SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 70 ASIA-PACIFIC SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 71 SOUTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 72 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 73 NORTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 74 EUROPE SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 75 ASIA-PACIFIC SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 76 SOUTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 77 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
